Discriminating orbital lymphoma from inflammation and correlating with histopathology using microstructure-based time-dependent diffusion MRI.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: suspected orbital tumors were prospectively enrolled between October 2023 and November 2024
I · Intervention 중재 / 시술
td-dMRI using oscillating gradient spin-echo (OGSE) and pulsed gradient spin-echo (PGSE) sequences on a 3 T scanner
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
추출되지 않음
[BACKGROUND] Preoperative discrimination between orbital B-cell lymphoma and inflammatory lesions remains a significant challenge using conventional imaging.
- p-value p < 0.001
- p-value p < 0.01
APA
Liu H, Zhao Y, et al. (2026). Discriminating orbital lymphoma from inflammation and correlating with histopathology using microstructure-based time-dependent diffusion MRI.. European journal of radiology, 196, 112699. https://doi.org/10.1016/j.ejrad.2026.112699
MLA
Liu H, et al.. "Discriminating orbital lymphoma from inflammation and correlating with histopathology using microstructure-based time-dependent diffusion MRI.." European journal of radiology, vol. 196, 2026, pp. 112699.
PMID
41610699
Abstract
[BACKGROUND] Preoperative discrimination between orbital B-cell lymphoma and inflammatory lesions remains a significant challenge using conventional imaging. This study evaluates the potential of time-dependent diffusion MRI (td-dMRI) alongside diffusion-weighted imaging (DWI) to improve differential diagnosis.
[METHODS] Patients with suspected orbital tumors were prospectively enrolled between October 2023 and November 2024. All participants underwent td-dMRI using oscillating gradient spin-echo (OGSE) and pulsed gradient spin-echo (PGSE) sequences on a 3 T scanner. Microstructural parameters-including cell diameter (d), cellularity, extracellular diffusivity (Dex), and intracellular volume fraction (Vin)-were derived. Correlations between apparent diffusion coefficient (ADC), d, cellularity, and histopathological metrics were assessed through quantitative morphometric analysis. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis.
[RESULTS] Forty-eight patients were enrolled (20 orbital MALT lymphoma, 28 inflammatory lesions). All parameters showed excellent interobserver agreement (ICCs: 0.82-0.93). Strong correlations were observed between histological cell diameter and d (r = 0.75), and between histological cellularity and both td-dMRI-derived cellularity (r = 0.71) and ADC (r = -0.74) (all p < 0.001). Lymphomas exhibited significantly lower ADC, d, and Dex, and higher Vin and cellularity compared to inflammatory lesions (all p < 0.01). Cellularity demonstrated the highest discriminative power (AUC = 0.87), followed by Vin (AUC = 0.82), while ADC showed moderate performance (AUC = 0.74). No significant differences in diagnostic efficacy were observed among the parameters.
[CONCLUSIONS] The td-dMRI provides highly reproducible, histologically correlated biomarkers that effectively differentiate orbital lymphoma from inflammatory lesions, thereby enabling orbital lesion risk-stratification and providing valuable non-invasive characterization to complement conventional ADC-based assessment for preoperative diagnosis of orbital lesions.
[METHODS] Patients with suspected orbital tumors were prospectively enrolled between October 2023 and November 2024. All participants underwent td-dMRI using oscillating gradient spin-echo (OGSE) and pulsed gradient spin-echo (PGSE) sequences on a 3 T scanner. Microstructural parameters-including cell diameter (d), cellularity, extracellular diffusivity (Dex), and intracellular volume fraction (Vin)-were derived. Correlations between apparent diffusion coefficient (ADC), d, cellularity, and histopathological metrics were assessed through quantitative morphometric analysis. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis.
[RESULTS] Forty-eight patients were enrolled (20 orbital MALT lymphoma, 28 inflammatory lesions). All parameters showed excellent interobserver agreement (ICCs: 0.82-0.93). Strong correlations were observed between histological cell diameter and d (r = 0.75), and between histological cellularity and both td-dMRI-derived cellularity (r = 0.71) and ADC (r = -0.74) (all p < 0.001). Lymphomas exhibited significantly lower ADC, d, and Dex, and higher Vin and cellularity compared to inflammatory lesions (all p < 0.01). Cellularity demonstrated the highest discriminative power (AUC = 0.87), followed by Vin (AUC = 0.82), while ADC showed moderate performance (AUC = 0.74). No significant differences in diagnostic efficacy were observed among the parameters.
[CONCLUSIONS] The td-dMRI provides highly reproducible, histologically correlated biomarkers that effectively differentiate orbital lymphoma from inflammatory lesions, thereby enabling orbital lesion risk-stratification and providing valuable non-invasive characterization to complement conventional ADC-based assessment for preoperative diagnosis of orbital lesions.
🏷️ 키워드 / MeSH
- Humans
- Male
- Female
- Diffusion Magnetic Resonance Imaging
- Diagnosis
- Differential
- Middle Aged
- Orbital Neoplasms
- Lymphoma
- Aged
- Adult
- Prospective Studies
- Inflammation
- 80 and over
- Reproducibility of Results
- Diffusion-weighted imaging
- Key words: Orbital lymphoma
- Orbital inflammatory lesion
- Time-dependent diffusion MRI
같은 제1저자의 인용 많은 논문 (5)
- From feasibility to translational pathways: a bibliometric and knowledge-mapping analysis of urine-based liquid biopsy in urologic cancers (2015-2025).
- The Current Status of Radionuclide Tumor Targeting Diagnosis and Therapy Based on FAP-2286: From Preclinical Studies to Clinical Application.
- Cleavage-Resistant CYLD Protects Against Autoimmune Hepatitis.
- Single-Cell Computational Frameworks for Quantifying BET Bromodomain Inhibitor Resistance and Screening Re-Sensitizer Drugs in Triple-Negative Breast Cancer.
- Target-Centric Multiplexed Screening of an Herbal Extract Identifies a Novel Dual A/A Receptor Antagonist for Cancer Immunotherapy.